Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
ACICLOVIR
Anti-infectives · Anti-infectives · Level 3
|
NEURAMINIDASE INHIBITORS
Anti-infectives · Anti-infectives · Level 3
|
AZOLES
Anti-infectives · Anti-infectives
|
AMPHOTERICIN B
Anti-infectives · Anti-infectives · Level 3
|
GANCICLOVIR
Anti-infectives · Anti-infectives · Level 3
|
|---|---|---|---|---|---|
| Mechanism of action | - Inhibits nucleic acid synthesis |
inhibit neurominidase resulting in impaired viral release from infected cells. Neurominidase cleaves the sialic acid on the cell membrane allowing viral budding. |
Azoles disrupt ergosterol production by interacting with 14-alpha demthylase, a cytochrome P450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of fungal cell membranes, inhibition of its synthesis leads to increased cell permeability causing leakage of contents. |
Polyenes specifically target fungal membranes. They bind ergosterol, which is the principal sterol in fungal membranes as opposed to cholesterol found in host membranes. This interference creates a transmembrane channel and the resultant change in permeability allows leakage of intracellular components |
— |
| Absorption | Erratic intestinal absorption and low bioavailability (25%). Oral valine-esterified prodrug valacyclovir improves absorption |
— | Well absorbed orally (except miconazole) |
only administered IV |
— |
| Distribution | Widely distributed |
— | Fluc – good CSF penetration |
Poor tissue penetration. Negligable CSF or urine penetration. |
— |
| Protein binding | — | — | Itra, Keto – 99% PB |
Highly protein bound |
— |
| Metabolism | Oral valine-esterified prodrug valacyclovir is rapidly hydrolyzed in the blood |
— | Fluc not metabolized well |
Metabolised by the liver |
— |
| Excretion | actively excreted in the kidneys unchanged (blocked by probenecid) |
— | Fluc – Urine unchanged |
poorly characterized but does not accumulate in renal failure |
— |
| Adverse Effects Toxicity | Renal |
1. Psychiatric symptoms |
Fluc: N/V/D, Abdominal pain |
Dose related nephrotoxicity |
— |
| Antimicrobial Spectrum | Herpes Simplex (1 and 2) and Varicella Zoster. |
— | Fluc: Candida |
Broad antifungal cover including candida, Cryptococcus, aspergillus and zygomyces |
— |
| Class Group | Antiviral |
Antiviral |
Antifungal |
Antifungal |
Antiviral |
| Introduction | Synthetic nucleoside analogue |
Oseltamivir and Zanamivir |
Triazoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole |
Polyene |
— |
| Legacy Cicm Level | Level 3 |
Level 3 |
Level 3 |
Level 3 |
Level 3 |
| Resistance Mechanism | — | — | Fluc: Some candida species, Decreased drug concentration |
— | — |
| Special Points | — | — | potent CYP inhibitors with a wide range of drug interactions (including warfarin) |
— | — |